Pacific Biosciences of California (PACB) Stock Forecast & Price Target
Pacific Biosciences of California · NASDAQ
$1.36+0.01 (+0.37%)
15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering Pacific Biosciences of California, 1 rate it Buy or better, 1 sit at Hold, and 1 rate it Sell or worse, a hold consensus. Targets are tightly clustered, $1.50 to $2.00, so the covering firms are broadly aligned. The average target of $1.83 sits 34% above the current $1.36. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.13 next quarter toward $-0.40 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Hold
Strong Buy00%
Buy133%
Hold133%
Sell133%
Strong Sell00%
Based on 3 analysts giving stock ratings to Pacific Biosciences of California.
As of Jul, 1 of 3 firms rate PACB a Buy (1 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
PACB EPS & revenue forecast
EPS · NEXT QUARTER
$-0.13
Range $-0.13 – $-0.12 · 5 analysts · +6% YoY
Next period, 5 analysts expect Pacific Biosciences of California to earn $-0.13 a share (range $-0.13 – $-0.12), versus $-0.12 a year earlier. Full-year consensus is $-0.51, growing to $-0.40 the year after.
REVENUE · NEXT QUARTER
$43.1M
Range $42.3M – $44.0M · 5 analysts · +12% YoY
Revenue is expected to reach $43.1M (range $42.3M – $44.0M), +12.2% year-over-year. Full-year consensus is $167.8M, rising to $194.0M next year.
Top analysts covering Pacific Biosciences of California
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PACB.
#1
Ross Osborn
Cantor Fitzgerald · Rank #139
Buy
$3.50+156.4% to target
Overall win rate
34%
+ Follow
#2
KM
Kyle Mikson
Canaccord Genuity · Rank #192
Buy
$3.00+119.8% to target
Overall win rate
35%
+ Follow
#3
Luke Sergott
Barclays · Rank #194
Sell
$1.50+9.9% to target
Overall win rate
41%
+ Follow
#4
SJ
Sung Ji Nam
Scotiabank · Rank #196
Buy
$2.00+46.5% to target
Overall win rate
45%
+ Follow
#5
Matthew Sykes
Goldman Sachs · Rank #226
Hold
$1.50+9.9% to target
Overall win rate
37%
+ Follow
PACB stock forecast FAQ
What is PACB's average 12-month price target?+
The 3 analysts with a live target average $1.83 for Pacific Biosciences of California over the next 12 months, ranging from a $2.00 high to a $1.50 low.
Is PACB stock a Buy, Sell or Hold right now?+
The current consensus is Hold. Of the 3 analyst ratings, 1 are Buy or Strong Buy, 1 are Hold, and 1 are Sell or Strong Sell.
What are the highest and lowest price targets for PACB?+
The Street-high target is $2.00 (Piper Sandler), and the Street-low is $1.50 (Barclays). The average of all 3 active targets is $1.83.
How many Wall Street analysts cover PACB?+
3 analysts have an active rating on Pacific Biosciences of California, and 3 firms carry a live 12-month price target.
Who is the most accurate analyst covering PACB?+
Among analysts who currently cover PACB, Ross Osborn of Cantor Fitzgerald has the strongest overall Quantellect track record (Rank #139). Their current call is Buy with a $3.50 target.
What is Pacific Biosciences of California's projected EPS for next quarter?+
The consensus estimate is $-0.13 per share (range $-0.13 – $-0.12) across 5 analysts. Full-year EPS is projected at $-0.51, rising to $-0.40 the following year.
How much revenue is Pacific Biosciences of California expected to report next quarter?+
Consensus revenue is $43.1M (range $42.3M – $44.0M). Full-year revenue is projected at $167.8M, growing to $194.0M next year.
Have analysts been upgrading or downgrading PACB lately?+
As of Jul, 1 of 3 firms rate PACB a Buy (1 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PACB calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
